New targeted drug shows promise for Hard-to-Treat cancers in early trial
NCT ID NCT06235983
First seen Jun 12, 2026 · Last updated Jun 12, 2026
Summary
This early-phase study tested an experimental drug called LY3537982 in 12 Chinese patients with advanced solid tumors that have a specific KRAS G12C mutation. The main goal was to measure how the drug moves through the body and to check its safety. Researchers also looked for signs that the drug might shrink tumors, but this is not a cure and ongoing treatment may be needed.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMORS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Jilin Cancer Hospital
Changchun, Jilin, 132000, China
-
The First Affiliated Hospital, Zhejiang University
Hangzhou, Zhejiang, 310003, China
-
Zhejiang Cancer Hospital
Hangzhou, Zhejiang, 310022, China
Conditions
Explore the condition pages connected to this study.